Latham & Watkins represented MedAlliance in the transaction. Swiss-based medical technology company MedAlliance announced it has entered into an agreement with Cordis for an acquisition which includes...
You must be a Standard 1 Year member to access this content.
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented LG Chem in the transaction, while WilmerHale LLP represented AVEO. LG Chem, Ltd. (KOSPI: 051910) entered into a definitive agreement to acquire...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Nordic Capital in the transaction. Nordic Capital, a leading private equity investor, and Equashield have announced that Nordic Capital has joined Equashield’s...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Spectrum Pharmaceuticals in the deal. Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, has entered into...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Alpine, while Latham & Watkins represented to underwriters in the offering. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) has announced the pricing...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented IDEAYA, while Davis Polk advised the representatives of the several underwriters in the offering. IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced the pricing of an...
You must be a Standard 1 Year member to access this content.
Cooley represented Mirum Pharmaceuticals, while Latham & Watkins represented the underwriters in the offering. Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Obsidio on the deal, while Latham & Watkins represented Boston Scientific Corporation. Boston Scientific Corporation announced the acquisition of Obsidio, Inc.,...
You must be a Standard 1 Year member to access this content.
Foley & Lardner LLP represented Health Care Service Corporation (HCSC) on the deal, while Latham & Watkins LLP represented Trustmark in the transaction. Health Care Service Corporation...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented MeiraGTx in the transaction. MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, announced a financing agreement with affiliates...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Arcutis Biotherapeutics, Inc. in the offering, while Cooley represented the underwriters. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the pricing of its underwritten...
You must be a Standard 1 Year member to access this content.
